Zydus Cadila announced on Thursday that USFDA has approved it to market Ibrutinib Capsules, 70 mg and 140 mg.
According to the USFDA letter, Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib capsules, 70 mg. for these capsules, the company will have 180 days of shared generic drug exclusivity. The 70 mg capsules have a brand sales of USD 32.5 mn, while 140 mg has a brand sales of USD 745.9 mn. Zydus is the first company to receive approval for generic Ibrutinib 70 mg capsules.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…